Amgen Inc. is plugging away with the cholesterol drug Repatha (evolocumab), which had just $27m in worldwide sales in the second quarter, amid continued reimbursement challenges, and has hopes that launching a monthly version of the drug will give it an edge.
Amgen’s Repatha and Sanofi/Regeneron Pharmaceuticals Inc.’s competing PCSK9 inhibitor Praluent (alirocumab) were approved in the summer of 2015,...



